卵巢上皮性肿瘤肠粘液抗原的癌胚抗原的免疫组织化学研究

应用两种肠粘液抗原和ＣＥＡ对７８例卵巢上皮性肿瘤石蜡标本进行免疫组分染色。三种抗原在良性和交界性肿瘤以腔缘分布为主，可见恶性肿瘤腔缘，胞浆弥漫分布并随组织学级的增高趋向于胞浆分布；三种抗原的阳笥率在浆液性癌和粘液性癌中的判别不显著，但ＣＥＡ在浆性癌中表达强度低于粘液性癌；在子宫内膜样癌中三抗原之阳性率和表达强度均较低，故可以辅助鉴别浆液性癌，粘液性癌和宫内膜样癌。     

子宫内膜间质肉瘤的病理形态和免疫组化特征

对１０例子宫内膜间质肉瘤的病理形态和免疫组化作了分析，ＥＳＳ在形态上可出现卵巢性索样上皮，平滑肌细胞样分化和血管外皮瘤样结构；在免疫组化上可出现Ｄｅｓｍｉｎ，Ｃｙｔｏｋｅｒａｔｉｎ，ＥＭＡ阳性等异常抗原表达。故应注意ＥＳＳ和恶性中胚叶混合瘤以及子宫的平滑肌肿瘤相鉴别。     

抗桥粒单抗在石蜡切片诊断上皮性肿瘤的应用…

应用抗桥粒ＤｓｅｍｏｐｌａｋｉｎⅠ单克隆抗体，采用多重ＰＡＰ及多重ＰＡＰ＋ＡＢＣ法提高检测方法的敏感性，借以显示常规石蜡切片中的桥粒多肽ＤＰＩ抗原，并结合角蛋白和上皮细胞膜抗原对上皮性肿瘤中ＤＰＩ的表达情况作了对比研究，结果表明：阳性染色呈弥漫颗粒状或包涵体样形态分布在瘤细胞浆内，多数上皮性肿瘤中与Ｋｅｒａｔｉｎ及ＥＭＡ染色结果一致，部分Ｋｅｒａｔｉｎ和ＥＭＡ阳性肿瘤中也有表达。间叶组织及其肿瘤呈     

子宫内膜上皮内癌合并腹膜癌病

子宫内膜上皮内癌 (ｅｎｄｏｍｅｔｒｉａｌｉｎｔｒａｅｐｉｔｈｅｌｉａｌｃａｒｃｉｎｏｍａ,ＥＩＣ)是新近报道的一种类型。Ａｍｂｒｏｓ等给ＥＩＣ的定义为 :ＥＩＣ是子宫内膜表面和腺上皮被类似侵袭性浆液性癌的恶性细胞所取代的非侵袭性病变。ＥＩＣ常合并子宫侵袭性浆液性癌 (ｕｔｅｒｉｎｅｓｅｒｏｕｓｃａｒｃｉｎｏｍａ ,ＵＳＣ) ,有人认为ＥＩＣ是ＵＳＣ的前驱病变 ,其细胞形态也很似ＵＳＣ的细胞 ,但是无内膜间质或平滑肌浸润。不合并ＵＳＣ且发生播散的ＥＩＣ很少见 ,其临床生物学意义还不清楚。作者报道 3例不合并ＵＳＣ的…     

生物素─链霉亲和素系统在检测巨细胞病毒抗体中的应用

本文用自制ＣＭＶ抗原和生物素－链霉亲和素系统试剂，通过最适条件的对比，建立了检测人血清中抗巨细胞病毒ＩｇＭ、ＩｇＡ类抗体的ＢＳＡ－ＥＬＩＳＡ，并与普通ＥＬＩＳＡ作比较，结果表明，ＢＳＡ－ＥＬＩＳＡ的非特异性吸附明显低于普通ＥＬＩＳＡ，与普通ＥＬＩＳＡ相比，抗体效价分别提高５和７倍，阳性率分别提高６８％和１５３．５％。在实际工作中曾用ＢＳＡ－ＥＬＩＳＡ检测临床样品１６５份，就所得结果进行分析。表明ＢＳＡ－ＥＬＩＳＡ检测ＣＭＶＩｇＭ和ＩｇＡ可提高特异性和灵敏度，值得推广应用。     

生物素─链霉亲和素系统在检测巨细胞病毒抗体中的应用

本文用自制ＣＭＶ抗原和生物素－链霉亲和素系统试剂，通过最适条件的对比，建立了检测人血清中抗巨细胞病毒ＩｇＭ、ＩｇＡ类抗体的ＢＳＡ－ＥＬＩＳＡ，并与普通ＥＬＩＳＡ作比较，结果表明，ＢＳＡ－ＥＬＩＳＡ的非特异性吸附明显低于普通ＥＬＩＳＡ，与普通ＥＬＩＳＡ相比，抗体效价分别提高５和７倍，阳性率分别提高６８％和１５３．５％。在实际工作中曾用ＢＳＡ－ＥＬＩＳＡ检测临床样品１６５份，就所得结果进行分析。表明ＢＳＡ－ＥＬＩＳＡ检测ＣＭＶＩｇＭ和ＩｇＡ可提高特异性和灵敏度，值得推广应用。     

应用重组质粒pAM－HBsAg在果蝇细胞中表达乙型肝炎病毒表面抗原及基因免疫的初步研究

应用果蝇（ＤＳ２）表达系统，构建了含有乙型肝炎病毒表面抗原（ＨＢｓＡｇ）、摄金蛋白启动子（ＭＴｎ－ｐｒｏｍｏｔｅｒ）的共表达质粒ｐＡＭ－ＨＢｓＡｇ，转染细胞，经克隆，存活细胞株的培养上清液经硫酸铵沉淀、氯化铯（ＣＳＣｌ）密度梯度离心沉淀，获得的抗原用酶联免疫吸附试验（ＥＬＩＳＡ）、放射免疫分析（ＲＩＡ）法检测抗体，免疫吸印法（Ｗｅｓｔｅｒｎｂｌｏｔ）和电泳凝胶银染显色证实分子量为２３０００和２７０００，免疫电镜观察显示表达产物为２２ｕｍ球型颗粒，通过重金属离子（ＣｕＳＯ４、ＺｎＳＯ４）的诱导可增加抗原的表达量。用共表达质粒ｐＡＭ－ＨＢｓＡｇ的ＤＮＡ，注射Ｂａｌｂ／Ｃ小鼠的股四头肌。经ＥＬＩＳＡ、ＲＩＡ检测抗体产生情况，结果免疫后的小鼠经硫酸锌喂养抗体高于普通喂养的小鼠。Ｓｏｕｔｈｅｒｎ杂交证实鼠肌肉细胞存在ＨＢｓＡｇ基因。小鼠免疫接种实验表明，ＤＳ２细胞表达的抗原与直接用ＤＮＡ含有ＨＢｓＡｇ的重组质粒）免疫小鼠均获抗ＨＢｓＡｇ的抗体。     

抗子宫内膜抗体和子宫内膜异位症

目的：研究抗子宫内膜抗体与子宫内膜异位症的关系。方法：改良法提取，纯化正常人及内异症患者的子宫内膜抗原，分析其氨基酸组成，并用ＳＤＳ－ＰＡＧＥ及Ｗｅｓｔｅｒｎ ｂｌｏｔ分析两者蛋白质组成及抗原特异性，建立ＥＬＩＳＡ方法并测定，分析正常人及内异症患者血清ＥＭＡｂ。     

人巨细胞病毒单克隆抗体的研制检定和应用

采用人巨细胞病毒（ＨＣＭＶ）ＡＤ１６９株作为免疫原，制备出１３株鼠－鼠杂交瘤细胞系。对其中的６株进行了检定．免疫印迹试验结果表明：单克隆抗体（ＭｃＡｂ）７Ｂ４、７Ｄ７、７Ｅ１１、８Ｅ８和８Ｄ６相对应的ＨＣＭＶ多肽分子量分别为４６、１５０、３８、５１７２和６５ｋＤ．ＨＣＭＶ感染人胚肺二倍体细胞（２ＢＳ）后不同时间制成抗原片，与ＭｃＡｂ作间接免疫荧光试验。结果表明：ＭｃＡｂ８Ｂ８相应的病毒多肽为即刻早期抗原，其它５株ＭｃＡｂ相应的病毒多肽均为晚期抗原，６株ＭｃＡｂ等量混合后，标上辣根过氧化物酶，用于ＩｇＭ抗体捕获法ＥＬＩＳＡ（ＭａｃＥＬＩＳＡ）中，并与间接ＥＬＩＳＡ（ＩＥＬＩＳＡ）同时检测ＨＣＭＶ－ＩｇＭ．在未经选择的１００份脐带血中，两法均为阳性的３份，两法均为阴性的９４份；ＭａｃＥＬＩＳＡ阳性而ＩＥＬＩＳＡ阴性的２份血清的特异性试验证明，ＨＣＭＶ－ＩｇＭ确为阳性．ＩＥＬＩＳＡ阳性而ＭａｃＥＬＩＳＡ阴性的１份血清的特异性试验证明，它是由ＲＦ引起的假阳性。     

VIRTUAL IMPLANTATION IN COMPUTER ASSISTED KNEE SURGERY

ＶＩＲＴＵＡＬＩＭＰＬＡＮＴＡＴＩＯＮＩＮＣＯＭＰＵＴＥＲＡＳＳＩＳＴＥＤＫＮＥＥＳＵＲＧＥＲＹＶＩＲＴＵＡＬＩＭＰＬＡＮＴＡＴＩＯＮＩＮＣＯＭＰＵＴＥＲＡＳＳＩＳＴＥＤＫＮＥＥＳＵＲＧＥＲＹＴ．ＷＡＮＧ，Ｇ．ＺＯＮＧ（ＲｏｂｏｔｉｃｓＲｅｓｅａｒｃ...     

Inappropriate mucin production in gall bladder metaplasia and neoplasia–an immunohistological study

This study demonstrates the presence of three antigens in glandular metaplasia occurring in patients with cholecystitis and cholelithiasis: specifically carcinoembryonic antigen (CEA), large intestinal mucin antigen (LIMA) and small intestinal mucin antigen (SIMA). These antigens could not be detected in normal gall bladder mucosa or in squamous metaplasia of the gall bladder. The occurrence of the three intestine-associated antigens in three carcinomas was irregular. In one mucinous carcinoma, only SIMA could be demonstrated. In one adenocarcinoma, SIMA was present in small areas of mucinous change, whilst CEA was present in the nonmucinous malignant tissue. In a mixed mucinous and non-mucinous adenocarcinoma with widespread dissemination, the three antigens were present both in the primary tumour and the metastases. These observations suggest that all forms of glandular metaplasia of the gall bladder are intestinal in nature and at least a proportion of gall bladder carcinomas are of an intestinal type. Finally they provide further immunological evidence that glandular metaplasia of the gall bladder should be considered a pre-malignant condition.     

S-100 Protein in Ovarian Tumors

The distribution of S 100 protein in 135 ovarian tumors, of which 127 were epithelial, was investigated using the im-munoperoxidase method. S 100 protein has been demonstrated previously in tumors of various origins. The present study further revealed its characteristic distribution in common epithelial tumors of the ovary. S 100 protein was present in 69% of serous tumors (benign, 50%; borderline, 100%; malignant, 71%), as well as in the serous elements of serous & mucinous mixed tumors (30%). S 100 protein was also demonstrated in 25% of clear cell carcinomas and 29% of endometrioid carcinomas. Interestingly, none of the mucinous tumors were positive for S 100 protein. In addition, the expression of S-100 protein by epithelial ovarian tumors was compared with that of CA 125 and carcinoembryonic antigen (CEA). The distribution of S 100 protein was similar to that of CA 125, since both antigens were frequently present in serous tumors, although their expression patterns were different. On the other hand, S 100 protein positive cases were almost negative for CEA or vice versa. Our observations indicate that demonstration of S 100 protein in common epithelial tumors of the ovary and comparison of S-100 protein distribution with that of CA 125 and CEA may further clarify the characteristics of common epithelial tumors of the ovary.     

S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases

The distribution of S-100 protein in 135 ovarian tumors, of which 127 were epithelial, was investigated using the immunoperoxidase method. S-100 protein has been demonstrated previously in tumors of various origins. The present study further revealed its characteristic distribution in common epithelial tumors of the ovary. S-100 protein was present in 69% of serous tumors (benign, 50%; borderline, 100%; malignant, 71%), as well as in the serous elements of serous & mucinous mixed tumors (30%). S-100 protein was also demonstrated in 25% of clear cell carcinomas and 29% of endometrioid carcinomas. Interestingly, none of the mucinous tumors were positive for S-100 protein. In addition, the expression of S-100 protein by epithelial ovarian tumors was compared with that of CA 125 and carcinoembryonic antigen (CEA). The distribution of S-100 protein was similar to that of CA 125, since both antigens were frequently present in serous tumors, although their expression patterns were different. On the other hand, S-100 protein-positive cases were almost negative for CEA or vice versa. Our observations indicate that demonstration of S-100 protein in common epithelial tumors of the ovary and comparison of S-100 protein distribution with that of CA 125 and CEA may further clarify the characteristics of common epithelial tumors of the ovary.     

WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms

We investigated whether a panel of antibodies including WT1 could separate pancreaticobiliary and ovarian carcinomas by staining 64 pancreaticobiliary adenocarcinomas, 41 ovarian serous carcinomas, and 12 primary ovarian mucinous neoplasms with WT1, cytokeratin (CK) 17, CK20, carcinoembryonic antigen (CEA), and CA-125. Moderate or strong intensity reactivity in more than 25% of cells was a positive result. Of the ovarian serous carcinomas, 38 (93%) were WT1 reactive and 22 (54%) WT1 positive, 9 (22%) had CK20 reactivity, and 3 (7%) were CK20 positive in fewer than 50% of cells. All were CK17 or CEA nonreactive. Of the ovarian mucinous neoplasms, all were WT1 and CK17 nonreactive and 11 (92%) were CEA reactive, 8 (67%) CEA positive, 10 (83%) CK20 reactive, and 6 (50%) CK20 positive. Of the pancreaticobiliary adenocarcinomas, 19 (30%) were CK20 positive, 27 (42%) CK17 positive, and 52 (81%) CEA positive. All were WT1 nonreactive. A panel including WT1, CK17, CK20, and CEA is useful to distinguish pancreaticobiliary and ovarian serous carcinomas. Extensive CK17 reactivity is supportive of a pancreaticobiliary adenocarcinoma when the differential diagnosis includes ovarian mucinous neoplasm. None of the antibodies positively identified ovarian mucinous neoplasms.     

Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary.

The expression of sialyl-Tn and Tn antigens in various benign, borderline, and malignant ovarian tumors was examined immunohistochemically using newly developed antibodies specific for sialyl-Tn and Tn antigens. Sialyl-Tn antigen was detected in only one benign tumor, a mucinous adenoma that showed faint cytoplasmic staining in a few cells. However, sialyl-Tn was present in 5 of 12 serous borderline tumors, 10 of 19 mucinous borderline tumors, 10 of 13 serous adenocarcinomas, 15 of 16 mucinous adenocarcinomas, 14 of 15 endometrioid adenocarcinomas, and 7 of 7 clear cell carcinomas of the ovary. The antigen expression was observed throughout the cytoplasm of cancer cells and in the apical cytoplasm and luminal contents of some glands. The incidence and intensity of staining for sialyl-Tn antigen were higher in malignant tumors than in borderline tumors, but these results did not correlate with the histologic classification or differentiation. Coexpression of sialyl-Tn antigen and Tn antigen was observed in two serous adenocarcinomas, six mucinous borderline tumors, five mucinous adenocarcinomas, eight endometrioid, and seven clear cell carcinomas. In no case was Tn antigen expressed without concomitant sialyl-Tn antigen expression. Accumulation of sialyl-Tn antigen seems to be an early event of carcinogenesis of the ovary.     

卵巢粘液性及浆液性囊腺瘤癌胚抗原的免疫组化研究

以CEA单克隆抗体,双PAP法研究卵巢粘液性和浆液性囊腺瘤组织内CEA的定位。结果表明:良性瘤23例,CEA全部(-)。交界性肿瘤中粘液性22例,CEA(+)者21例;浆液性15例,CEA(+)者7例。恶性肿瘤中粘液性23例,CEA(+)者18例,浆液性37例,CEA(+)者7例。由于粘液性交界性肿瘤有较高的CEA检出率,可作为诊断参考指标。     

Chordoma. Antibodies to epithelial membrane antigen and carcinoembryonic antigen in differential diagnosis

Seven chordomas, chondrosarcomas, and mucinous colorectal carcinomas, five liposarcomas, and five ependymomas were evaluated for the presence of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) by using an immunoperoxidase technique. All of the chordomas and mucinous carcinomas were cytoplasmic EMA positive, while the chondrosarcomas, liposarcomas, and ependymomas were negative. Among the tumors that were studied, only the mucinous carcinomas were positive for CEA. The EMA positivity of a chordoma reflects its epithelial nature and is a valuable aid in making the differential diagnosis between a chordoma and nonepithelial tumors, while the absence of CEA in a chordoma aids in making the distinction between a chordoma and a mucinous carcinoma.     

Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.

Cables, a cyclin-dependent kinase (cdk) interacting protein, has recently been identified and mapped to human chromosome 18q11. Cables appears to be primarily involved in cell cycle regulation and cell proliferation. Overexpression of Cables in Hela and other cell lines inhibits cell proliferation and tumor formation. We hypothesize that loss of Cables expression is associated with ovarian cancer. To test our hypothesis, we examined Cables expression in the four most common subtypes of ovarian carcinomas: serous, endometrioid, mucinous, and clear cell. In addition, mucinous and serous borderline tumors were also included. Loss of Cables expression was observed at high frequency in ovarian serous (11 of 14 cases, 79%) and endometrioid (5 of 10 cases, 50%) carcinomas. In contrast, strong Cables staining was detected in all clear cell carcinomas (10 cases) and mucinous tumors (5 carcinomas and 5 borderline tumors). The majority of serous borderline tumors (11 of 14 cases, 79%) showed positive Cables staining, with the rest showing focal loss of Cables expression. Furthermore, RT-PCR revealed the lack of Cables mRNA in a human ovarian cancer xenograft. No correlation was noted between loss of Cables and histologic grade, tumor stage, and survival. In conclusion, our results indicate that loss of Cables is common in ovarian serous and endometrioid carcinomas and imply that Cables may be involved in the pathogenesis of these two types of ovarian carcinomas.     

Immunohistochemical and ultrastructural localization of T antigen in ovarian tumors.

Thomsen-Friedenreich (T) antigen, the immediate precursor antigen of the human blood group MN system, has been found in many carcinomas, but it is suppressed in normal tissues and nonmalignant diseases. Using a monoclonal antibody specific for the T epitope and an indirect immunoperoxidase technique at light and electron microscopic levels, the authors studied the expression of T antigen and its potential diagnostic value in ovarian tumors. Among 30 serous and mucinous ovarian cystadenocarcinomas, 20 (67%) were positive and 10 (33%) were negative for T antigen. In carcinomas, positive rates increased in parallel with the tumor grade and were 37%, 75% and 80% for grade 1, 2, and 3 tumors, respectively. Of the nine patients with metastasis, seven (78%) had positive and two had negative reactions in their primary and metastatic tumors. T antigen staining was observed at the intraluminal cell surfaces and peripheral cell membranes. The ultrastructural localization of T antigen revealed electron-dense reaction products at the cell surface and microvillous surfaces. Of the ten benign ovarian tumors, three (30%) were weakly positive and seven (70%) were negative for T antigen. These findings indicate a positive correlation between the presence of immunoreactive T antigen and conventional unfavorable prognostic indicators in ovarian carcinoma. The surface location of T antigen suggests that it may have a functional role at the cell membrane and the membrane may be involved in secretion (shedding) of T antigen. Detection of T antigen may be a useful marker of prognosis in ovarian carcinoma.     

Expression and mutational analysis of c-kit in ovarian surface epithelial tumors

Coexpression of Kit ligand and c-kit has been reported in some gynecologic tumors. To determine whether imatinib mesylate is useful in ovarian epithelial tumors, we performed immunohistochemical and mutational analysis. The cases consisted of 33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear cell carcinomas. Five cases of serous cystadenoma and 5 cases of mucinous cystadenoma were also included. In the immunohistochemical study, 3 cases (3/6, 50%) of borderline mucinous cystic tumor and two cases (2/8, 25%) of mucinous cystadenocarcinoma show positive staining for KIT protein. Only one case (1/13, 7.7%) of serous cystadenocarcinoma had positive staining. On mutational analysis, no mutation was identified at exon 11. However, two cases of borderline mucinous tumors and one case of mucinous cystadenocarcinoma had mutations at exon 17. In these cases, the immunohistochemistry also shows focal positive staining at epithelial component. Although, KIT protein expression showed higher incidence in mucinous tumors than serous tumors, they lack KIT-activating mutations in exon 11. Thus, ovarian surface epithelial tumors are unlikely to respond to imatinib mesylate.